Deutschland
- Deutsch
España
- Español
Italia
- ItalianoChemotherapy-induced Nausea and Vomiting
Sancuso is for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult.1
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com
Sancuso is for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult.1
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com
Chemotherapy-induced Nausea and Vomiting
Provided by
KKI NewCo (known as Grunenthal Meds)
Sancuso transdermal patch is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic multi-day chemo therapy in adult patients with swallowing difficulties.1
Click here for prescribing and adverse event reporting information.
-
References
1. SANCUSO 3.1 mg/24 hours transdermal patch SPC.
KKI/INT/KKI/0607 November 2023